William Blair analyst Ryan Daniels has reiterated their bullish stance on EVH stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Daniels has given his Buy rating due to a combination of factors including Evolent Health’s solid third-quarter performance and the company’s strategic positioning in the market. Despite a recent pullback in stock price, which has created an attractive valuation, Daniels sees a compelling risk/reward profile.
Furthermore, the company’s focus on value-based specialty care and its large addressable market contribute to a strong growth outlook. While there is some uncertainty regarding 2026 earnings due to pending enrollment trends in ACA and Medicare Advantage, Daniels believes that upcoming clarity on these trends will benefit the stock. Overall, the unique market position and robust growth prospects of Evolent Health support the Buy rating.
In another report released today, Stephens also upgraded the stock to a Buy with a $7.00 price target.